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Abstract
Purpose Standards for surgical decisions are unavailable, hence treatment decisions can be personalized, but also introduce 
variation in treatment and outcome. National registrations seek to monitor healthcare quality. The goal of the study is to 
measure between-hospital variation in risk-standardized survival outcome after glioblastoma surgery and to explore the 
association between survival and hospital characteristics in conjunction with patient-related risk factors.
Methods Data of 2,409 adults with first-time glioblastoma surgery at 14 hospitals were obtained from a comprehensive, 
prospective population-based Quality Registry Neuro Surgery in The Netherlands between 2011 and 2014. We compared the 
observed survival with patient-specific risk-standardized expected early (30-day) mortality and late (2-year) survival, based 
on age, performance, and treatment year. We analyzed funnel plots, logistic regression and proportional hazards models.
Results Overall 30-day mortality was 5.2% and overall 2-year survival was 13.5%. Median survival varied between 4.8 and 
14.9 months among hospitals, and biopsy percentages ranged between 16 and 73%. One hospital had lower than expected 
early mortality, and four hospitals had lower than expected late survival. Higher case volume was related with lower early 
mortality (P = 0.031). Patient-related risk factors (lower age; better performance; more recent years of treatment) were sig-
nificantly associated with longer overall survival. Of the hospital characteristics, longer overall survival was associated with 
lower biopsy percentage (HR 2.09, 1.34–3.26, P = 0.001), and not with academic setting, nor with case volume.
Conclusions Hospitals vary more in late survival than early mortality after glioblastoma surgery. Widely varying biopsy 
percentages indicate treatment variation. Patient-related factors have a stronger association with overall survival than hospital-
related factors.
Keywords Glioblastoma · Neurosurgical procedures · Quality of health care · Outcome assessment · Mortality · Survival
Introduction
The aim of glioblastoma surgery is to maximize tumor 
removal, while preserving the patient’s functional integrity. 
Because guidelines for surgical decision making are not 
available, treatment decisions can be highly personalized, 
but can introduce treatment variation and outcome varia-
tion as well. If the neurosurgeon considers a tumor unre-
sectable, or if the patient is considered unfit or unmotivated 
for resective surgery, then a diagnostic biopsy can be done. 
More extensive tumor removal is associated with longer 
patient survival [1–3], whereas functional deficits from too 
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extensive resections can result in poorer quality of life and 
shorter survival [4]. Before and during surgery, care teams 
use different techniques to optimize resections due to (1) 
varying access to image-guided navigation, fluorescence-
guided microscopy, intraoperative MRI, or brain stimula-
tion mapping (2) different surgical schools of education, i.c. 
more oncological or functional, and (3) diverging experts’ 
opinions on more aggressive or conservative approaches. 
None of these techniques has been proven to prolong patient 
survival.
Patient survival outcome after glioblastoma surgery var-
ies considerably in reports from tertiary referral centers 
[1–3, 5–17]. Likewise, patient survival may differ among 
the hospitals within a nation.
The Dutch Society for Neurosurgery [18] established 
the Quality Registry for Neuro Surgery [19], starting with 
a consensus set of indicators for glioblastoma surgery in 
2011. This registry provides feedback to all hospitals with 
neurosurgical units on clinical practice for self-assessment 
and quality-monitoring.
In this study, we measured variation in risk-standardized 
early mortality and late survival after glioblastoma surgery 
between all 14 hospitals that perform glioblastoma surgery 
in the Netherlands. Furthermore, we explored the associa-
tion between survival and hospital characteristics, including 
case volume, academic setting and biopsy percentage, in 
addition to known prognostic patient characteristics, i.e. age 
and performance status.
Methods
We studied all 2409 patients who had first-time surgery for 
glioblastoma between January 1, 2011 and December 31, 
2014 at all 14 hospitals engaged in glioblastoma surgery in 
The Netherlands. We collected data for patients 18 years or 
older at surgery and a histopathological diagnosis of glio-
blastoma according to the WHO 2007 criteria [20].
Data collection
Neurosurgeons, nurse specialists in neuro-oncology and 
trained physician assistants prospectively entered patient 
data in the Quality Registry for Neurological Surgery. 
Demographic and clinical information consisted of age at 
diagnosis, gender, Karnofsky performance status before 
surgery, type of surgery (biopsy or resection), and dates of 
treatment, last follow-up and death. A surgical procedure 
was considered a biopsy, when tissue was taken for diagnosis 
only, either by needle biopsy or open biopsy. For the patients 
who had died within one month after surgery, the cause of 
death was retrieved if available from the medical records or 
by contacting the primary care physician.
Treatment decisions for patients were made in multi-
disciplinary tumor board meetings in all hospitals. During 
resective surgery image-guided navigation was customarily 
used. Fluorescence-guided resection, stimulation mapping, 
and ultrasonography was applied by neurosurgeons’ prefer-
ences. Intraoperative MRI was not in use.
The dates of death were verified and updated against the 
information available from the National Cancer Registry 
(NCR). The NCR collects information on all newly-diag-
nosed cancer patients in the Netherlands following notifica-
tion by the national pathology registry. Information on vital 
status is retrieved through yearly linkage with the Municipal 
Personal Records Database; on March 1, 2016 for our analy-
ses. As a further data quality check, each hospital reviewed 
their data after the closure of patient inclusion.
Because this data was collected for evaluation of qual-
ity of care in accordance with the Dutch Quality Act for 
Healthcare [21], written informed consent was not needed. 
Ethical approval was waived because the study was not sub-
ject to the Medical Research Involving Human Subjects Act 
(WMO) [22] and de-identified data had been collected of 
patients mostly not alive. After delivery by a trusted third 
party [23], de-identified patient data was analyzed. Four 
authors (PWH, AZW, VHO, PRO) had full access to this 
data and are responsible for the data analysis and reporting.
Outcomes and risk predictors
The main outcome measures to evaluate variation were spec-
ified in the consensus set of quality indicators of the registry: 
the risk-standardized early mortality and late survival. Early 
mortality was defined as the percentage of patients who had 
died of any cause within 30 days after surgery; late survival 
was defined as the percentage of patients who were alive at 
2 years (730 days) after surgery.
To account for risk differences in glioblastoma patients 
among hospitals, we used known patient-related predictors 
for survival as covariates, i.e. age at diagnosis and Karnof-
sky performance status [24, 25]. We also included the year 
of treatment for risk-standardization, because of the four 
year timespan in which care decisions may have changed, 
although national treatment guidelines did not alter [26]. 
Clinical management decisions were not included in risk-
standardization, such as corticosteroid use [27], surgical 
technique and extent of resection [1–3], and participation 
in clinical trials [28, 29], although associated with survival. 
Standard adjuvant treatment consisted of 60 Gy fractionated 
conformal radiotherapy with concomitant temozolomide 
chemotherapy, and six cycles of adjuvant temozolomide 
[30]. Hospital characteristics that we explored for associa-
tion with outcome were the total number of patients with 
glioblastoma treated in 4 years in a hospital (i.e. volume), 
academic setting, and the percentage of biopsy procedures.
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Statistical analysis
Survival was analyzed in days with censoring at the last date 
of follow-up or the lookup date of alive status, and analy-
ses were based on complete cases regarding information on 
covariates.
A multivariable hierarchical Cox proportional hazards 
model was used for risk-standardization in assessing out-
come variation between hospitals. For statistical modeling 
and inferences, outcomes were assessed at patient-level 
using age, performance and year of treatment as covari-
ates for risk-standardization. A random effect per hospital 
was included in the model in recognition of imperfect risk-
standardization [31, 32]. Thus, for each patient, a predicted 
survival function was obtained based on the patient-related 
covariates and a hospital random effect of 0, representing 
treatment in a fictitious hospital with average performance. 
Using the patient-specific expected survival function, the 
standardized risk for having died within 30 days and for 
being alive by 730 days was calculated for each patient. In 
calculating risk-standardized ratios per hospital, we obtained 
the predicted probability of the events for each patient in a 
hospital and summed these probabilities to get the expected 
number of events for that hospital. Risk-standardized ratios 
per hospital were calculated as the observed number of 
events divided by the predicted number of events, i.e. the 
observed-to-expected ratio [32, 33]. For example, the risk-
standardized early mortality is lower than expected with a 
ratio below one, and risk-standardized late survival is higher 
than expected with a ratio above one.
We applied a Bayesian predictive model with random 
effects using the Stan language [34, 35]. The counting pro-
cess of events over time was assumed to follow a log-poisson 
density with unknown means and unknown precisions for the 
regression coefficients, the random effects and the hazards 
for which we used vague priors. Vague priors were chosen to 
primarily reflect inference from the presented data without 
substantive prior knowledge. Model details are provided as 
online code [36] and the predictive patient risk model as web 
application [37]. The posterior predictive model was verified 
using simulated data. No evidence against convergence was 
identified. The median values of posterior distributions were 
used as estimates with 95% credibility intervals.
Funnel plots were generated with expected number of 
events as precision and risk-standardized observed-to-
expected event ratios per hospital as indicator as previously 
described [31]. The funnel control limits to identify potential 
outliers were obtained as 95% and 99% prediction limits 
from the Poisson distribution.
As a first exploration to plot regression lines between the 
hospital-related characteristics and observed early mortal-
ity and late survival, we used univariate logistic regression 
with death status at 30 days and alive status at 2 years as 
response measure [31]. For volume, log-transformed num-
ber of patients was modelled. Second, to estimate the effect 
sizes of hospital and patient-related characteristics on overall 
survival, we used the multivariable hierarchical Cox pro-
portional hazards model. The hazard ratios for death were 
determined with 95% confidence intervals for hospital char-
acteristics, i.e. log volume, academic setting, and biopsy 
percentage, and for patient-related characteristics, i.e. age, 
performance status, and year of treatment, as risk-standard-
ization without hospital random effects [38].
Results
Of the 2,409 patients, 2,308 were available for complete case 
analysis (Table 1). At last follow-up, 462 patients were alive.
The observed overall survival over time per hospital and 
the risk-standardized survival function for all patients are 
plotted in Fig. 1. The observed and expected survival over 
time per hospital is shown in Supplemental Fig. 1.
The overall 30-day mortality was 5.2% and the overall 
2-year survival was 13.5%. The observed early mortality and 
late survival for each hospital is listed in Table 1. Median 
overall survival was 10.2 months, and varied between 4.8 
and 14.9 months among hospitals.
The hospital characteristics of case volume, academic 
setting and biopsy percentage are plotted in relation to 
observed early mortality and late survival in Fig. 2. Case 
volume varied between 73 and 358 patients in 4 years. In 
univariate logistic regression analysis, a higher volume was 
related with lower early mortality (P = 0.031), but not with 
late survival. The estimated log OR of log volume on early 
mortality was − 0.39, so that a 10% increase in volume was 
estimated to be associated with 3.9% relative decrease in 
early mortality. The estimated boundary from higher-than-
average to lower-than-average early mortality is located at a 
volume of about 180 patients in 4 years, i.e. 45 patients per 
year. In this first univariable exploration, an academic setting 
of hospitals was not significantly associated with early mor-
tality or late survival. The biopsy percentage varied between 
16 and 73% among hospitals, indicating considerable treat-
ment variation. The biopsy percentage was not significantly 
associated with early mortality or late survival in this first 
exploration.
In our effort to retrieve the causes of early death, infor-
mation was obtained for all 119 patients who had died 
within 30 days. Early death was related to glioblastoma 
progression in 36 (30%) patients, the cause remained 
unknown in 36 (30%), death was directly related to surgery 
in 31 (26%), i.e. hemorrhage in 16, postresection edema 
and/or ischemia in seven, postoperative functional deterio-
ration in seven, and intracranial infectious complications 
in three. Early death could be indirectly related to surgery 
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in 13 (11%), i.e. seizures in five, pulmonary embolus in 
five, and extracranial infectious complications in three, 
and early death was unrelated to either the disease or sur-
gery in three (3%), i.e. cardiac arrest in two, and trauma 
in one.
From the funnel plots in Fig. 3, one hospital (b) had lower 
early mortality than expected within 95% control, and four 
hospitals (a, i, k, and n) had lower late survival than expected 
within 95% control. The combination plot of early mortal-
ity and late survival indicates that the two outcomes are not 
related. In other words, this indicates that more extensive 
surgery for longer tumor control is not set off by an increase 
in postoperative mortality.
In the multivariable Cox regression analysis, the known 
prognostic factors of older age (HR 1.54, 1.46–1.62, 
P < 0.00001) and worse performance (HR 0.77, 0.74–0.81, 
P < 0.00001) were strongly associated with shorter survival, 
as expected. More recent years of treatment were also asso-
ciated with longer survival with 2011 as reference (2012 HR 
0.94, 0.83–1.07, NS; 2013 HR 0.80, 0.71–0.92, P = 0.001; 
2014 HR 0.78, 0.68–0.89, P = 0.0003). Therefore, risk-stand-
ardization with these patient-related characteristics seems 
justified. Of the hospital characteristics, a lower biopsy 
percentage was associated with longer overall survival (HR 
2.09, 1.34–3.26, P = 0.001). Log case volume (HR 0.954, 
0.866–1.05) and academic setting (HR 0.951, 0.858–1.05) 
were not associated with overall survival.Ta
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hospital in colors and overall survival function in black based on the 
Cox regression model with risk-standardization for age, performance, 
and treatment year. The hospital identifications correspond with 
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Discussion
This comprehensive, nation-wide, four-year prospective 
quality registry study on survival outcomes after glio-
blastoma surgery shows (1) between-hospital variation in 
2-year survival and 30-day mortality (2) surgical treatment 
variation suggested by widely-varying biopsy percentages 
between hospitals (3) that 30-day mortality is not a suit-
able measure for glioblastoma surgery-related complications 
only, as many of these patients die early from progressive 
disease (4) that a larger case volume is associated with 
lower early mortality, but not with overall survival (5) that 
in addition to patient-related factors, i.e. younger age and 
better performance, a lower biopsy percentage in a hospital 
is an important indicator of overall survival outcome, and 
not case volume nor an academic setting.
Differences in late survival after glioblastoma surgery 
between hospitals have not been published. The 2-year sur-
vival of glioblastoma in our overall data is comparable to 
other registries, i.e. 14.8% in the Central Brain Tumor Reg-
istry of the United States [39] and 23.8% in the Surveillance, 
Epidemiology and End Results Program of the National 
Cancer Institute [40], and comparable to other communi-
ties, ranging from 12.0 to 25.3% [9, 15–17]. Registry-based 
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populations include patients typically excluded from clinical 
trials and surgical resection series, such as elderly patients 
with treatment concessions, resulting in shorter survival in 
real-life data than reported in clinical trials.
Early mortality differences between hospitals have been 
reported earlier, indicating that high-volume surgeons in 
high-volume hospitals have lower in-hospital mortality and 
complication rates after brain tumor surgery based on the 
Nationwide Inpatient Sample data of 62,514 admissions 
[41]. Similarly, high-volume hospitals had lower mortality 
after brain tumor resections based on a state-based study of 
4,723 patients in 33 hospitals [42]. Postoperative mortality 
estimates for brain tumor surgery have varied considerably: 
0.26% in 8,091 patients based on a meta-analysis of 90 pub-
lications [43], 1.0% in 306 patients from one hospital [4], 
1.5% in 408 patients from 52 hospitals [44], 1.7% in 400 
patients from one hospital [45], 2.5% in 322 patients in a 
multicenter randomized trial [46], 3.5% in 4,723 patients 
from 33 hospitals [42], and 7.9% in 834 patients from 19 
hospitals [9]. Variability in these estimates may be explained 
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Fig. 3  Multipanel plot of expected numbers of early deaths versus 
risk-standardized mortality ratios (a), expected numbers of late survi-
vors versus risk-standardized late survival ratios (b), and combination 
plot of risk-standardized early mortality versus late survival ratios on 
log scales (c). The solid funnels are 95% control limits, the dotted 
funnels 99% control limits. Black dots indicate hospitals with ratios 
outside the 95% control limits. Better than expected early mortality 
and late survival is shown in green, worse than expected is shown in 
red. The institutional identifications are printed in the circles; sizes 
correspond with the case volumes according to the legend. Note that 
hospital i has 0 observed late survivors and 0.89 expected late survi-
vors, which therefore is outside the plot below the lower 99% control 
limit and in the red region
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by different timings of mortality, inclusion of tumors other 
than glioblastoma, patient selection bias, and publication 
bias. Our results indicate that mortality within 30 days is not 
a useful quality indicator for glioblastoma surgery-related 
complications without information on causes of death. A 
more precise measure would be the percentage of surgery-
related mortality.
Earlier reports have identified an association between 
larger case volumes and more favorable outcome after glio-
blastoma surgery [41, 42, 47] and after other cancer-related 
surgery [48, 49]. In our findings, larger case volume is not 
associated with overall survival when adjusted for patient-
related risk factors. Patient-related factors clearly outweigh 
hospital-related effects. A prominent hospital-related pre-
dictor of overall survival in our data is the percentage of 
biopsies. One explanation is that higher extent of resection 
has been shown to prolong patient survival [1–3]. In addi-
tion, we speculate that the percentage of biopsies may be a 
surrogate marker for a more conservative general approach 
with possibly earlier cessation of therapies to rescue or to 
prolong life. The biopsy percentages among hospitals varied 
considerably, whereas the patient risk profiles of hospitals 
were quite similar. The causes for the biopsy percentage var-
iation and MRI-based glioblastoma removal measurements 
need to be explored as quality indicators in further studies. 
This should enhance exchange of team expertise and surgi-
cal skills. Other quality indicators for glioblastoma surgery 
may include functional outcome, measured as patient-related 
outcome measures, cognitive performance, or health-related 
quality of life. Furthermore, the National Surgical Quality 
Improvement Program recently reported on hospital process 
measures, such as length of hospital stay [50], readmission 
rate [51], and unplanned reoperation [52].
Our results highlight the importance of risk-standardiza-
tion in comparing hospital outcomes [31, 32]. For example, 
hospital ‘d’ has the highest observed percentage of 2-year 
survival without risk-adjustment (23% in Table 1), whereas 
the 2-year survival ratio adjusted for patient-related risk 
factors is less than expected within control limits (0.88 in 
Fig. 3b). This can be explained by a patient population that is 
on average younger and has better performance than popula-
tions of other hospitals (Table 1). This may indicate a deviat-
ing patient referral or selection in hospital ‘d’.
Survival time is an objective measure. The interpretation, 
however, of early mortality or late survival as success or fail-
ure of treatment decisions is not necessarily straightforward. 
For example, a patient not alive at 30 days may have died 
from rapidly progressive disease despite optimal treatment 
decisions, whereas a patient alive at 2 years may be in a 
poor condition with minimal quality of life for a prolonged 
period of time from overtreatment. Therefore, a spectrum 
of quality indicators is required to capture the nuances of 
quality of care.
The yearly feedback of our registry and the results of this 
analysis have resulted in discussions on quality-monitoring 
within our workgroup and in self-assessment by neurosurgeons 
within departments. This collaboration has been perceived 
as constructive and encouraging. The observation that more 
recent treatment years were associated with longer overall sur-
vival may indicate a quality improvement as a result of this 
collaboration.
The strengths of our study are the comprehensive popula-
tion-based nation-wide cohort, the data quality checks from 
two data sources (QRNS and NCR), the near-complete fol-
low-up of patients, and the modern methods for prediction 
modeling. The limitations of our study are the unavoidable 
imperfect patient-level risk-standardization, the unavailability 
of information - other than biopsy or resection - on applied sur-
gical techniques and the unavailability of other hospital char-
acteristics, such as treatment guideline adherence or clinical 
trial participation. Furthermore, the few patients who refrained 
from any treatment or who had radiation or chemotherapy 
without histopathological diagnosis were not included in this 
pathology-based registry. Similarly, the few patients, who may 
have crossed over between hospitals for treatment, remain uni-
dentified. And treatment variation other than surgical decisions 
may contribute to the observed outcome variation. For this, we 
have recently started a national multidisciplinary collaboration 
involving radiation and medical oncologists, neurologists, radi-
ologists, and pathologists for a joined quality registry, i.e. the 
Dutch Brain Tumor Registry.
There are several possible implications for clinical practice. 
First, a quality program is required to enforce hospitals with 
less than expected outcome to improve, for instance by identi-
fication of differences in care programs amenable to exchange 
expertise, and to ultimately devise a systematic quality evalua-
tion and improvement cycle. At the same time regionalization 
of brain tumor care in networks may improve overall qual-
ity of care. Second, further investigation is necessary into the 
relation between hospital biopsy percentage, volume, and sur-
vival outcome. It remains undetermined whether a threshold 
for minimum case load per year is a robust criterium for ‘in 
control’ survival outcome. Third, early mortality should be 
reported with causes of death in quality comparisons. Fourth, 
patient counseling and surgical decision making should rather 
be based on personalized predictions from real practice data 
than on clinical trial results and tertiary referral center publica-
tions [53]. Therefore, our predictive patient risk model may be 
useful in clinical decision making [37].
Conclusion
Hospitals vary more in late survival than early mortality 
after glioblastoma surgery. Widely varying biopsy percent-
ages indicate treatment variation. Patient-related factors have 
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a stronger association with overall survival than hospital-
related factors.
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